Clicky

Vivoryon Therapeutics NV(VVY)

Description: Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.


Keywords: Cancer Immunotherapy Treatment Of Cancer Alzheimer's Disease Cell Therapy Therapeutic Products Peptides Amyloidosis Treatment Of Alzheimer's Disease Amyloid Beta Fraunhofer Institute Molecular Neuroscience

Home Page: www.vivoryon.com

Weinbergweg 22
Halle, 06120
Germany
Phone: 49 345 555 9900


Officers

Name Title
Dr. Ulrich Dauer Chairman of the Management Board & CEO
Dr. Michael Schaeffer Chief Bus. Officer & Member of the Management Board
Mr. Florian Schmid CFO & Member of Management Board
Dr. Manuela Bader Director of Investor Relations & Communications
Mr. Frank T. Weber M.D. Chief Medical Officer
Dr. Konrad Glund Co-Founder & Advisor
Dr. Hendrik Liebers Advisor

Exchange: AS

Country: NL

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 10.5067
Price-to-Sales TTM: 24.1411
IPO Date:
Fiscal Year End: December
Full Time Employees: 14
Back to stocks